TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: plasma concentration of quercetin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentration of isorhamnetin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death or rehospitalization at 60 days
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with severe tachycardia or hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in self-care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptance of screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Development of SUI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Vp-Ls distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BCTQ (Boston Carpal Tunnel Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DML (Distal Motor Latency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CMAP (Compound Muscle Action Potential)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CSA (Cross-sectional Area) of the median nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Leg Plp measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of leg edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Form-36 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median survival time to extubation
Endpoint domain: Mortality/survival
Primary endpoint: Seizures occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: lower leg vascular resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean reduction in HbA(1)c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in mean fasting plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in triglycerides and HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean duration of NAB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median intragastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical Global Impression rating of 'very much improved'
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in Hamilton Rating Scale for Depression scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of responders on Clinical Global Impressions-Improvement scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean %TWL (Total Weight Loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean %EWL (Excess Weight Loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Days to abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of spinal manipulation compared to diclofenac and placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Night-driving score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected near-vision score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflow pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: brain relaxation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of platelet P-selectin expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inhibition of activated GPIIb-IIIa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Aggressive behavior symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attention problems symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxious/depressed symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention time for buffered saline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort rating return to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for oral administration of misoprostol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in CIN I‐II‐III cervical lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in CIN II‐III cervical lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: gastric pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: quality-adjusted life years gained
Endpoint domain: Mortality/survival
Primary endpoint: 3-year survival for patients with an aortic root aneurysm
Endpoint domain: Mortality/survival
Primary endpoint: 3-year survival for patients with an ascending aortic aneurysm
Endpoint domain: Mortality/survival
Primary endpoint: 3-year freedom rate from grade 3 to 4 aortic insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ToP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life benefit
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical discomfort score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inhaled clearance (CL/F) of FF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-24) for Asian patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central volume of distribution (Vc/F) for Asian patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: standardized cost per patient for 30 days of treatment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: final manifest refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall image quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for angiographic stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for angiographic stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in storage symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speech perception outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain-derived neurotrophic factor (BDNF) serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbound fraction of paliperidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paliperidone IR tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with antibiotic concentrations > MIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with antibiotic concentrations > 5 x MIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for supplementary analgesics in the first 24 h
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Central retinal thickness increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aqueous flare at 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best corrected visual acuity gain at 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kyn/Trp ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Allantoin/uric acid (All/UA) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of mechanical failure of leads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of nonischemic cardiomyopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: scores of mild erectile dysfunction (ED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sexual desire (SD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum 8‐OHdG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visualization of metastatic RCC lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor: blood ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum antibody concentrations to all antigens tested
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: geometric mean ratio of anti-Ptox neutralizing antibody per unit of IgG anti-Ptox antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of ARDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Successful rescue rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consent to health record linkage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk of a fall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lag-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: TTPeak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Severity of alcohol withdrawal syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability (no adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in number of awakenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Improvement in wake time after sleep onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Improvements in MOS sleep disturbance and sleep quantity subscales
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Improvement in physical function (ASPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in physical function (BASFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum postoperative pain scores on exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-operative opioid requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anaesthesia induction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Achieving target HbA1c of < 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications during the trial
Endpoint domain: Adverse events/effects
Primary endpoint: mean symptom score for flatulence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: bowel movement frequency to pass watery faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Trough exercise duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angina attacks reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of convalescence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Health anxiety (Whiteley-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychosocial distress (PHQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: relative weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of helping 1 more person achieve the BP goal (<140/90 mm Hg)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost of helping 1 more person achieve good refill adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prescription drug costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CK release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone turnover marker (B‐NTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total MSSQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in CNS symptoms (depression, anxiety, panic disorders)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: latency in rapid eye movement (REM) sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phospholipid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: endometrial histology assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: scheduled bleeding pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Scores on the Expectancy scale of the Alcohol Craving Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on the ACQ Purposefulness subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: observer-rated depressed mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-reported depressed mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lower demineralization (%DM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher remineralization (%RM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of cardiovascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pain scores during induced cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC stiffness scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of decline in SVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: short-term recall of CVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7- and 30-day nonsmoker prevalence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost per attributable quit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: downregulation of gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal nighttime sleep duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Infant nighttime awakenings
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Maximum length of nighttime sleep for infants
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: K-MMSE scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SNSB-II memory domain percentile score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: K-MBI scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidences of ventricular arrhythmia, no‐reflow and slow flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TIMI grade 3 occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CCFmax(HR) following bed rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CCFmax of mean arterial blood pressure (mBP) after HDBR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of grade 3 skin toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency of moderate to very severe VMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of objective VMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphine consumption during the first 2 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain scores at 2, 6, 12, and 24 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spinal range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: strength of trunk flexors and extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve of atorvastatin acid (AUC(0-72))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve of atorvastatin lactone (AUC(0-72))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve of active and total HMG-CoA reductase inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of pathological OGTTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IGFBP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Seroconversion rate after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Seroprotection rate after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Mean geometric mean titre (GMT) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom from AF recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: relief of breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: safety (especially renal)
Endpoint domain: Adverse events/effects
Primary endpoint: ADHD and oppositional defiant disorder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in fundus pulsations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in choroidal and optic disc blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Risk of Type 2 Diabetes (T2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle strength and RFD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work ability index score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Median time to treatment initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesic effect of caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Median number of treatments to clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Remission rate after six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Response to 1-24ACTH stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Chronic lung disease incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in fasting small and dense LDL particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid profile outcomes
Primary endpoint: Increase in postprandial large HDL particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid profile outcomes
Primary endpoint: Decrease in lipoprotein insulin resistance score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjective pain and discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall tolerance during FEES
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma PCSK9 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: interleukin-6 serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of plasma concentrations > or = 0.05 mumol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes